PRA Health Sciences Inc. (PRAH)

104.28
3.76 3.48
NASDAQ : Commercial Services
Prev Close 108.04
Open 107.49
Day Low/High 104.22 / 107.66
52 Wk Low/High 79.20 / 121.98
Volume 563.38K
Avg Volume 472.90K
Exchange NASDAQ
Shares Outstanding 65.53M
Market Cap 7.17B
EPS 2.40
P/E Ratio 46.43
Div & Yield N.A. (N.A)

Latest News

Keep Your Head Up: Cramer's 'Mad Money' Recap (Thursday 12/6/18)

Keep Your Head Up: Cramer's 'Mad Money' Recap (Thursday 12/6/18)

Jim Cramer offers his views on how to hang on in scary markets.

Care Innovations® And PRA Health Sciences Announce Strategic Partnership

Care Innovations® And PRA Health Sciences Announce Strategic Partnership

As part of Care Innovations ® focus on expanding into adjacent markets, the company is proud to announce its exclusive global partnership with PRA Health Sciences (NASDAQ:PRAH).

Private Briefing: KKR's Healthcare Deal Spree

Private Briefing: KKR's Healthcare Deal Spree

The healthcare team led by James Momtazee has been very busy, with deals for PharMerica, American Medical Response and Covenant Surgical Partners, among others.

Short Interest Falls 24.3% For PRAH

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 380,230 share decrease in total short interest for PRA Health Sciences Inc , to 1,186,518, a decrease of 24.27% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Parexel Is Discovering the Drugs of the Future

Parexel Is Discovering the Drugs of the Future

The midcap drug maker is finding growth as an outsourcing destination.

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone Bought and Sold in the Fourth Quarter

Private equity firms' publicly traded equity holdings are a valuable source of ideas for growth and value investors, alike.

TheStreet Quant Rating: A (Buy)